Cover Image
市場調查報告書

纖維肉瘤 : 開發平台分析

Fibrosarcoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 321906
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
纖維肉瘤 : 開發平台分析 Fibrosarcoma - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 57 Pages
簡介

纖維肉瘤是由纖維性結締組織發病的惡性腫瘤,症狀有疼痛、腫、局部發熱、血管擴張痛、骨骼肥大、病理性骨折、神經及血管的變化等。

本報告提供纖維肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

纖維肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

開發治療藥的企業

  • Advanced Proteome Therapeutics Corporation
  • Advenchen Laboratories, LLC
  • Elsalys Biotech SAS
  • Novartis AG
  • Plexxikon Inc.
  • Rigontec GmbH
  • 大日本住友製藥

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AL-3818
  • APC-103
  • DSR-6434
  • everolimus
  • ImOl-100
  • KRA-0008
  • LK-3
  • MAT-303
  • PLX-7486
  • SEN-461

最新的開發平台資訊

開發暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9102IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Pipeline Review, H1 2017, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibrosarcoma - Overview
    • Fibrosarcoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibrosarcoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibrosarcoma - Companies Involved in Therapeutics Development
    • Advanced Proteome Therapeutics Corp
    • Advenchen Laboratories LLC
    • Bicycle Therapeutics Ltd
    • Daiichi Sankyo Company Ltd
    • Elsalys Biotech SAS
    • Intezyne Technologies Inc
    • Novartis AG
    • Pharma Mar SA
    • SOM Biotech SL
    • Sumitomo Dainippon Pharma Co Ltd
  • Fibrosarcoma - Drug Profiles
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APC-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BT-1718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daunorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-6434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELB-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LK-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MI-130110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEN-461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOM-0777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibrosarcoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Fibrosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corp, H1 2017
  • Fibrosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Fibrosarcoma - Pipeline by Bicycle Therapeutics Ltd, H1 2017
  • Fibrosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H1 2017
  • Fibrosarcoma - Pipeline by Intezyne Technologies Inc, H1 2017
  • Fibrosarcoma - Pipeline by Novartis AG, H1 2017
  • Fibrosarcoma - Pipeline by Pharma Mar SA, H1 2017
  • Fibrosarcoma - Pipeline by SOM Biotech SL, H1 2017
  • Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Fibrosarcoma - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Fibrosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top